1 / 38

ARV therapy in children - Clinical & Pharmacological Effects: How much do we know and how much do we need to know?

ARV therapy in children - Clinical & Pharmacological Effects: How much do we know and how much do we need to know?. Mark Cotton KID-CRU, Tygerberg Children’s Hospital Avy Violari PHRU, University Witwatersrand South Africa. ILF Forum, CROI 2009, Montréal. How much do we know? A great deal

kerri
Télécharger la présentation

ARV therapy in children - Clinical & Pharmacological Effects: How much do we know and how much do we need to know?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARV therapy in children - Clinical & Pharmacological Effects: How much do we know and how much do we need to know? Mark Cotton KID-CRU, Tygerberg Children’s Hospital Avy Violari PHRU, University Witwatersrand South Africa ILF Forum, CROI 2009, Montréal

  2. How much do we know? • A great deal • How much do we need to know? • A great deal more • How can we better implement what we already know? • A lot better?

  3. Research Questions • When to start • What to start • Can you interrupt

  4. Evolving MTCT issues • Single dose Nevirapine • Protecting the tail (for the mother) • Truvada • ZDV + LMV • Urgent need for more ARV choices for children - where enhanced PMTCT fails • ARVs to breast-feeding mothers • ARVs to breast-fed infants

  5. Cumulative mortality of HIV-infected African infantsNewell ML et al Lancet 2004; 364: 1236-43

  6. AIDS 2009; 23: 101-106

  7. Annual post-neonatal deaths (X), Age 1-11 months, & antenatal HIV prevalence (%) (--), South Africa, 1990-2002

  8. Observed and fitted likely HIV/AIDS-related deaths, Age 1-11 months, South Africa, 1997-2002

  9. Non-HIV/AIDS-related deaths, Age 1-11 months, South Africa, 1997-2002

  10. N Engl J Med 2008; 359: 2233-44

  11. CHER Trial - Hypothesis • Early limited ART until 1st or 2nd birthday will: • Have long-term benefit by delaying disease progression • And delaying the need for long-term continuous ART

  12. Screening & Enrolment Number of Participants prescreened: 5985 Number of Participants HIV+: 405 (6.8% of prescreened) Number of referred HIV+ participants: 155 Total Number of HIV+ Participants: 560 Number of Participants screened: 532 Participants enrolled CHER: 377 Participants with CD4<25%:104 (19.5%) Not enrolled for Other reasons:51

  13. Baseline characteristics

  14. 1.00 0.80 0.60 0.40 0.20 0.00 0 3 6 9 12 Early ART associated with reduced mortality P = 0.0002 Failure Probability Time to Death (months) Arm 1 Arm 2 & 3 Patients at risk

  15. Most frequent infections per 100 pt years Early ART Deferred

  16. Programmatic issues - ART <12 m of age • Single policy easy to implement • Majority infants need HAART in 1st year of life • Easier to manage if low transmission rates • Can implement without waiting for CD4 results • ARV education should start antenatally & must be “fast-tracked” when +ve PCR • Continues after ART started

  17. Mothers have many issues • May not be psychologically prepared • Own health • Often underestimated • Disclosure • Complex • Visits to grandparents • Lack of privacy • Infant feeding • TB exposure • Socio-economic

  18. Current diagnostic strategy for infants in lower income countries • WHO • 4-6 weeks of age • RSA - rigidly interpreted as 6w (immunization visit) • If unknown, establish exposure status at 1st contact with healthcare services

  19. Can we do earlier PCR’s • Do we know enough about pK in first 3 months of life?

  20. CD4% & death HPMCS Dunn et al Lancet 2003; 362: 1605-11 Number of Deaths

  21. 1st and 2nd line Regimens could be better • 1st line 3rd drug • Most African Countries • NVP • RSA • LPVR • NRTI component • RSA • 1st line D4T + 3TC • 2nd line ZDV + ddI • Abacavir reserved for lipoatrophy, lactic acidosis

  22. What is the best ARV strategy for children over a year of age? • Ongoing morbidity at all ages and levels of CD4 • USA - 1 to 5 y • CD4 <25% WHO - June 2008

  23. ARV toxicity • 127 uninfected infants born to HIV-infected mothers • HAART • Post natal ZDV • 61 had elevated lactate • 3 had minor self-limited developmental delay Pediatrics 2004; 114; e598

  24. ARV toxicity in 1st year of lifeCHER study Early Deferred

  25. MTCT - Paradigm shifts for ARV resistance • Single dose Nevirapine • Sd NVP + ZDV • HAART • Antenatal • Protection of breast-fed infants • ARVs to breast-feeding infants

  26. Long-term toxicity PENTA 11www.pentatrials.org • Cross-sectional survey • 477 children • Median age - 10y • Median ARV exposure - 4.5y • Central lipohypertrophy +/- peripheral lipo-atrophy - 25% • Dyslipidaemia - 33%

  27. Strategies • When to start - Older children • PREDICT - Thailand • Interruption studies • PENTA 11 - pilot exploratory study - CD4 strategy • BANA-2 - Botswana - CD4 guided approach • CHER trial - RSA • Ithemba - KZN, RSA

  28. ARV strategies • Neverest II - RSA • Can you switch from LPV/r to NVP once stable • Arrow - Zim, Uganda • Induction with 4 drugs and maintenance with 3 • Clinical versus Laboratory monitoring • PENPACT 1 • PI vs NNRTI • At what viral load to switch • P1060 - African Sites • PI vs NNRTI in NVP-exposed and non-exposed infants >6m • LPV/r monotherapy pilot trial - Thailand

  29. Rifampicin co-treatment • IMPAACT: EFV study for <3 years of age with and without TB • Double Dose LPV/r - CROI 2009 • Helen McIlleron & Colleagues, UCT

  30. pK studies for new and re-formulated drugs • Industry and Networks (IMPAACT) • Raltegravir • Vicirviroc • TMC 125 • Paediatric Alluvia® • etc

  31. Key points • Key requirements - minimal • Administration frequency • Impact on lifestyle • Minimum, non-toxic excipients • Convenient easy administration • Palatable • Requires minimal manipulation by HCWs • Ability for reliable division unit dose • Transportable, low bulk • Easily produced and stable in variety climates • Affordable • Commercially viable

  32. Flexible solid dosage forms • Mini-tablets / granules • Oro-dispersible • Or used for preparation of liquids • Can be dissolved in breast milk • Easy to manufacture • Cheaper than existing liquid formulations

  33. Research Needs • What particle size can be safely and comfortably ingested by infants & children at different developmental stages? • Optimize acceptability of dosage forms • Granularity • Texture • Standards for palatability testing

  34. WHO - 2008

  35. Vileness of taste directly proportional to importance • LPV/r - 1st line for NVP-exposed infants • RTV-boosted LPV/r needed for co-treatment with Rifampicin Ren et al, J Acquir Immune Defic Syndr, 2008 Jan 11 Ritonavir (RTV) (80mg/ml) Lopinavir/ritonavir (LPV/r) (80/2omg/ml)

  36. Acknowledgements • Elaine Abrams, Andy Wiznia, Tammy Meyers, Quianna Douglas • IMPAACT Primary Therapy Committee • Seminar December 8, 2008

More Related